PSU Institute for Computational and Data Sciences’ Symposium Builds Collaborations Across Disciplines

UNIVERSITY PARK, Pa., Dec. 3, 2020 — The Penn State Institute for Computational and Data Sciences’ 2020 virtual symposium brought together researchers, computational experts, government officials and industry specialists who are working to build interdisciplinary communities that can transform this deluge of data into a stream of solutions for the world’s most pressing scientific and societal challenges.

“We are here today because of data — More specifically, a deluge of data,” Jenni Evans, professor of meteorology and atmospheric science and director of the Institute for Computational and Data Sciences. “This deluge is especially evident in interdisciplinary research, where we are using a diversity of data to integrate multiple perspectives to address complex problems, often involving a diversity of data and the challenges that brings.”

She added that finding ways to use this data deluge to our advantage would also require support from industries outside of academia.

“ICDS has been partnering

Read More

Discovery Life Sciences and Scientist.com Partner to Advance Liquid Biopsy Development and Immunotherapy Research

SAN DIEGO–(BUSINESS WIRE)–Dec 3, 2020–

Scientist.com, the healthcare industry’s leading marketplace for outsourced research, and Discovery Life Sciences™ (Discovery), a global leader in biospecimen solutions, genomic, cell and immunohistochemistry (IHC) services, have partnered to offer researchers online access to Illumina’s TruSight™ Oncology 500 (TSO500) technology. The TSO500 technology was recently added to HudsonAlpha Discovery™, Discovery’s highly regarded sequencing and bioinformatics laboratory.

“HudsonAlpha Discovery’s TSO500 platform combined with Discovery Life Sciences’ comprehensive biospecimen solutions, which are also available through Scientist.com, will accelerate immuno-oncology and liquid biopsy biomarker studies through delivery of actionable NGS data across patient-matched tumor and plasma biospecimens,” stated Kevin Lustig, PhD, CEO and founder of Scientist.com. “This cutting-edge technology is now available to all Scientist.com users under one pre-established legal agreement, accelerating preclinical research and enabling faster science.”

Illumina’s TSO500 solid Tumor (FFPE) and ctDNA technology enables genomic characterization across a broad range of tumor types through the

Read More

Hyliion Stock Could Be Science’s Version of Affidavits



a bicycle in front of a mirror: an electric vehicle charging. image represents ev stocks like fsr stock


© Source: nrqemi / Shutterstock.com
an electric vehicle charging. image represents ev stocks like fsr stock

With the massive push toward clean energy solutions, along with the allegedly growing acceptance in the White House regarding the future administration of President-elect Joe Biden, the narrative for Hyliion (NYSE:HYLN) appears robust. Since making its market debut, Hyliion stock has skyrocketed along with many electric vehicle and alternative fuel investments.



a bicycle in front of a mirror posing for the camera: an electric vehicle charging. image represents ev stocks like fsr stock


© Provided by InvestorPlace
an electric vehicle charging. image represents ev stocks like fsr stock

Even with Hyliion taking a sizable hit to its valuation since late September, shares have been incredibly profitable for early stakeholders.

Further, the bullish thesis for Hyliion stock seems much more practical than the full-electrification strategy. While EVs are known for their zero-emissions platform, the harsh reality is that they’re more expensive on an apples-to-apples comparison. And that’s because EV batteries are pricey, making them prohibitively

Read More

Biology Prof. Lue, Visionary in Life Sciences Pedagogy, Dies at 56 | News

In the sixteen years Gregory A. Llacer worked alongside Robert A. Lue, Llacer never knew Lue to be anything less than “an indefatigable advocate for science education,” “a blue-sky thinker,” and “a tireless humanist.”

“Rob was one of the first Harvard faculty members I got to know,” Llacer wrote in a Nov. 12 email to his staff at the Office of Undergraduate Research and Fellowships, which he directs. “Even in the throes of declining health due to cancer he was fighting throughout the summer, we still were working on ideas and projects, collaborations I intend to see through.”

Lue, an innovator in life sciences education, died on Nov. 11 at 56 of a fast-moving cancer.

Lue’s footprint at Harvard stretches wide. In addition to his role as a Molecular and Cellular Biology professor of practice, he served as founding faculty director of Harvard’s online education platform, HarvardX; the first faculty

Read More

Huge growth and Great Revenue generation future report of Natural Language Processing (NLP) in Healthcare and Life Sciences Market

Pune, New York, USA, November 27 2020 (Wiredrelease) Research Dive :This outbreak of COVID is projected to impact the global natural language processing (NLP) in healthcare and life sciences market in the positive manner. During to corona virus emergency period, many healthcare and pharmaceutical organizations across the globe are emphasizing their research activities to evaluate the effect of the virus, and quickly develop accurate and fast solutions. This factor is significantly impacting the demand for NLP technology due to increasing the utilization by researchers. NLP technology can help to find most effective clinical decision support through validation discovery of scientific knowledge and medical records. This factor is projected to accelerate the market growth in the pandemic time.

In addition, many governments are taking several initiatives to support the organizations during the COVID-19 pandemic period. For instance, the UK government has launched future fund for UK-based companies and they can apply

Read More

The Unconventional Guide to Natural Language Processing (NLP) in Healthcare and Life Sciences Market

Pune, New York, USA, November 18 2020 (Wiredrelease) Research Dive :This outbreak of COVID is projected to impact the global natural language processing (NLP) in healthcare and life sciences market in the positive manner. During to corona virus emergency period, many healthcare and pharmaceutical organizations across the globe are emphasizing their research activities to evaluate the effect of the virus, and quickly develop accurate and fast solutions. This factor is significantly impacting the demand for NLP technology due to increasing the utilization by researchers. NLP technology can help to find most effective clinical decision support through validation discovery of scientific knowledge and medical records. This factor is projected to accelerate the market growth in the pandemic time.

In addition, many governments are taking several initiatives to support the organizations during the COVID-19 pandemic period. For instance, the UK government has launched future fund for UK-based companies and they can apply

Read More

EVERSANA announces strategic partnership with Roivant Sciences to advance commercialization services and predictive analytics for healthcare

CHICAGO, BASEL, Switzerland and NEW YORK, Nov. 12, 2020 /PRNewswire/ — Roivant Sciences today named EVERSANA™, the pioneer of next-generation commercial services to the global life sciences industry, a preferred provider of commercial services worldwide. Under the agreement, EVERSANA and Roivant will partner on opportunities to improve the access, affordability and adherence of innovative therapies developed by Roivant. In addition, EVERSANA and Roivant will expand existing partnerships around multiple Roivant technology platforms, including deploying Alyvant’s salesforce app to enhance results for EVERSANA clients.

Roivant has a diverse pipeline of investigational drugs across its family of companies. In addition to its biopharmaceutical subsidiaries, Roivant also builds technology-focused platforms aimed at improving the process of developing and commercializing medicines.

EVERSANA, which is currently managing the launch of multiple pharmaceutical and digital therapies, offers a fully integrated commercial services platform designed to solve global pricing, access, reimbursement, real-world evidence, adherence

Read More

Discovery Life Sciences Becomes the Global Market Leader in Biospecimens with the Acquisition of Europe-based East West Biopharma

The acquisition creates the largest network of clinical collection sites in Europe, advancing Discovery Life Sciences’ position as the global market leader in biospecimen procurement

HUNTSVILLE, Ala., Nov. 9, 2020 /PRNewswire/ — Discovery Life Sciences™ (Discovery), a global leader in biospecimen, genomic sequencing, cell, and immunohistochemistry (IHC) services, announced today the acquisition of East West Biopharma, a leading human biospecimen contract research organization in Europe powered by the largest biocollection network in Ukraine. 

The addition of East West Biopharma builds on Discovery’s existing capability and creates Europe’s largest network of clinical collection sites that ethically obtain consented biospecimens from patients across multiple therapeutic areas to support the global medical research community.

“This acquisition represents the culmination of a highly productive and mutually successful partnership between our companies,” said Glenn Bilawsky, CEO of Discovery Life Sciences.  “East West Biopharma has a long-standing reputation for its commitment to quality,

Read More

Gilead Sciences or Abbott Laboratories?

The coronavirus pandemic in the U.S. is now in its third wave. For stock investors, it’s important to have at least one stock in your portfolio that can perform well amid the pandemic. Whether that’s a business that does testing, is working on a vaccine, or provides a treatment option for COVID-19, a good coronavirus stock can help generate some returns for the foreseeable future, while other investments may struggle during these challenging times. It’s also a great way to diversify your portfolio.



a woman sitting in a chair talking on a cell phone: Better Coronavirus Stock: Gilead Sciences or Abbott Laboratories?


© Provided by The Motley Fool
Better Coronavirus Stock: Gilead Sciences or Abbott Laboratories?

Two options are Gilead Sciences (NASDAQ: GILD) and Abbott Laboratories (NYSE: ABT). Gilead is well-known for its drug remdesivir, which can help treat patients with COVID-19, while Abbott has been a major player in testing for the virus. Let’s take a close look at these two companies to see which one is

Read More

Funding the Quiet Good: Gifts that Support the Humanities and Social Sciences | BU Today

Of the $42 billion the federal government spends on research and development each year, less than 5 percent ($1.9 billion) goes to social and behavioral science research. Photos courtesy of iStock, Unsplash, and Wikimedia

Humanities

They’re often small, but they change the world in big ways

  • Under 5 percent of the federal government’s R&D $42 billion goes to social and behavioral science research
  • In 2018, the Consortium of Social Science Associations ranked BU 9th of 530 colleges and universities in social science funding
  • Social scientists have helped Americans save for retirement, stem the spread of Ebola, and identified environmental factors contributing to obesity

When Jack Dorsey, the cofounder and CEO of Twitter and Square, donated $10 million to Boston University’s Center for Antiracist Research in mid-August, the gift was remarkable in the world of philanthropy for two reasons: the speed with which it arrived—only six weeks after the BU center

Read More